Hospira seeks to track adverse events linked to anticoagulants

Twitter icon
Facebook icon
LinkedIn icon
e-mail icon
Google icon

To help hospitals comply with 2010 Joint Commission National Patient Safety goals to prevent and reduce adverse events associated with anticoagulation therapy, Hospira has launched the Anticoagulation Assistant knowledge module.

Part of Hospira’s TheraDoc clinical surveillance platform, the Anticoagulation Assistant module will track patients who are administered anticoagulation therapy to prevent contraindications, therapeutic concerns or adverse drug events (ADEs).

According to Lake Forest, Ill.-based Hospira, a pharmaceutical and medication management company, 1.5 percent of patients on anticoagulants need prolonged hospitalization while 6.2 percent undergo and are affected by medical errors that require an intervention.

The company said the Anticoagulation Assistant is a dashboard solution equipped with an alert system, interventional documentation and a patient flag model for tracking anticoagulation therapy based on the Joint Commission standards.

The Anticoagulation Assistant can be used in correlation with Hospira’s Anticoagulation Alerts package, launched in 2009 within its TheraDoc expert system platform.